"Diphosphonates" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Organic compounds which contain P-C-P bonds, where P stands for phosphonates or phosphonic acids. These compounds affect calcium metabolism. They inhibit ectopic calcification and slow down bone resorption and bone turnover. Technetium complexes of diphosphonates have been used successfully as bone scanning agents.
| Descriptor ID |
D004164
|
| MeSH Number(s) |
D02.705.429.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Diphosphonates".
Below are MeSH descriptors whose meaning is more specific than "Diphosphonates".
This graph shows the total number of publications written about "Diphosphonates" by people in this website by year, and whether "Diphosphonates" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 2 | 0 | 2 |
| 2006 | 2 | 0 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 2 | 0 | 2 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 2 | 2 |
| 2019 | 0 | 2 | 2 |
| 2020 | 2 | 1 | 3 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 1 | 1 |
| 2024 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Diphosphonates" by people in Profiles.
-
Hydroxychloroquine and a low antiresorptive activity bisphosphonate conjugate prevent and reverse ovariectomy-induced bone loss in mice through dual antiresorptive and anabolic effects. Bone Res. 2024 Sep 05; 12(1):52.
-
The Case for Bisphosphonate Use in Astronauts Flying Long-Duration Missions. Cells. 2024 08 13; 13(16).
-
Randomised trial of genetic testing and targeted intervention to prevent the development and progression of Paget's disease of bone. Ann Rheum Dis. 2024 Mar 12; 83(4):529-536.
-
Approach to the Patient: Pharmacological Therapies for Fracture Risk Reduction in Adults With Osteogenesis Imperfecta. J Clin Endocrinol Metab. 2023 06 16; 108(7):1787-1796.
-
Early identification of a 12-bp tandem duplication in TNFRSF11A encoding receptor activator of nuclear factor-kappa B (RANK): Clinical characterization and response to bisphosphonate therapy. Bone. 2023 05; 170:116698.
-
A multicenter study to evaluate pain characteristics in osteogenesis imperfecta. Am J Med Genet A. 2023 Jan; 191(1):160-172.
-
Craniofacial and dental phenotype of two girls with osteogenesis imperfecta due to mutations in CRTAP. Bone. 2022 11; 164:116516.
-
Patterns of Osteoporosis Medications Selection After Drug Holiday or Continued Therapy: A Real-World Experience. Endocr Pract. 2022 Oct; 28(10):1078-1085.
-
Bisphosphonates, Bone and Joint Pain. Curr Osteoporos Rep. 2021 08; 19(4):417-428.
-
ATRAID regulates the action of nitrogen-containing bisphosphonates on bone. Sci Transl Med. 2020 05 20; 12(544).